Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus VECURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus VECURONIUM BROMIDE.
ATRACURIUM BESYLATE vs VECURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and causing skeletal muscle relaxation.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and muscle contraction.
0.4–0.5 mg/kg IV bolus for intubation; maintenance: 0.08–0.1 mg/kg IV as needed or infusion 5–10 mcg/kg/min
IV bolus: 0.08-0.1 mg/kg for intubation; maintenance: 0.01-0.015 mg/kg every 12-15 minutes as needed or continuous infusion 0.05-0.1 mg/kg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 20 minutes (range 15-25 min) in healthy adults. Clinical context: Recovery from neuromuscular blockade is faster than for nondepolarizing relaxants cleared renally. Half-life may be prolonged in hypothermia or acidosis but is minimally affected by renal or hepatic impairment.
Clinical Note
moderateAtracurium besylate + Tranilast
"Atracurium besylate may increase the neuromuscular blocking activities of Tranilast."
Clinical Note
moderateAtracurium besylate + Tolfenamic acid
"Atracurium besylate may increase the neuromuscular blocking activities of Tolfenamic acid."
Clinical Note
moderateAtracurium besylate + Nimesulide
"Atracurium besylate may increase the neuromuscular blocking activities of Nimesulide."
Clinical Note
moderateAtracurium besylate + Risedronic acid
Terminal elimination half-life: 1.2-1.9 hours (65-115 minutes). Clinically, recovery from neuromuscular blockade is faster than with pancuronium; prolonged in renal and hepatic impairment.
Renal (50-60% unchanged), biliary/fecal (20-30% as metabolites, mainly laudanosine), and Hofmann elimination (non-enzymatic, pH- and temperature-dependent) accounts for approximately 40-50% of clearance.
Primarily renal (40-60% unchanged in urine within 24 hours); biliary/fecal elimination accounts for <20%. Approximately 10-20% as 3-desacetylvecuronium (active metabolite) in urine.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker
"Atracurium besylate may increase the neuromuscular blocking activities of Risedronic acid."